Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: A prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study

American Journal of Cardiovascular Drugs

Volumn 9, Issue 2, 2009, Pages 91-101

  Ansquer, Jean Claude ^a   Bekaert, Ivan ^b,e   Guy, Martine ^a   Hanefeld, Markolf ^c,e   Simon, Alain ^d   Adam, Siegfried ^e   Arnould, Michel ^e   Assad, Nabil ^e   Baekelandt, Joost ^e   Battello, Giancarlo ^e   Bostoen, Gerrit ^e   Danet, Jacques ^e   De Marneffe, Guy ^e   De Ricke, Carl ^e   Dimon, Bernard ^e   Engelen, Marc ^e   Fischer, Steffen ^e   Flosi, Marc ^e   Fournier, Henri ^e   Freise, Daniela ^e   Gariepy, Jérôme ^e   Hauck, Peter ^e   Hersen, Bruno ^e   Koch, Markus ^e   Letzelter, Jean Marie ^e   Mantz, Sylvia ^e   Marmor, Philippe ^e   Mortelmans, Jacques ^e   Naudts, Ingomar ^e   Oldenburg, Wolfgang ^e   Rochet, Jean Pierre ^e   Saussez, Alain ^e   Scholz, Gerhard ^e   Timmermans, Freddy ^e   Valensi, Paul ^e   Weber, Hans Gert ^e   Wieland, Veronika ^e   Carewicz, Otmar ^e   more..

^a Laboratoires Fournier SA   (France)

^b General Hospital St Jozef   (Belgium)

^c Gesellschaft für Wissens und Technologietransfer   (Germany)

^d HÔPITAL BROUSSAIS   (France)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATINE KINASE; CREATININE; EZETIMIBE; FENOFIBRATE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GASTROENTERITIS; GLUCOSE METABOLISM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SIDE EFFECT; URTICARIA;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; AZETIDINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROCETOFEN;

EID: 63849120023     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03256580     Document Type: Article

References (25)

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97
2. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39
3. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78
4. Vrecer M, Turk S, Drinovec J, et al. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials. Int J Clin Pharmacol Ther 2003; 41 (12): 567-77
5. Fazio S, Linton MF. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr Atheroscler Rep 2004; 6 (2): 148-57
6. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95 (1): 69-75
7. Krentz AJ. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab 2003; 5 (Suppl. 1): S19-27
8. Sweeney ME, Johnson RR. Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol 2007; 3 (3): 441-50
9. Farnier M, Freeman MW, Macdonell G, et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005; 26: 897-905
10. Farnier M, Roth E, Gil-Extremera B, et al. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J 2007; 153: 335.e1-8
11. McKenney JM, Farnier M, Lo KW, et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006; 47: 1584-7
12. Sauron R, Wilkins M, Jessent V, et al. Absence of a food effect with a 145mg nanoparticle fenofibrate tablet formulation. Int J Clin Pharmacol Ther 2006; 44 (2): 64-70
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18 (6): 499-502
14. Jones H. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus. Am J Cardiol 2007; 99: 133-40
15. Gil-Extremera B, Mendez G, Zakson M, et al. Efficacy and safety of ezetimibe/simvastatin co-administered with fenofibrate in mixed hyperlipidemic patients with metabolic syndrome. Metab SyndromeRelat Disord 2007; 5 (4): 305-14
16. Kosoglou T, Statkevich P, Fruchart JC, et al. Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Curr Med Res Opin 2004; 20 (8): 1197-207
17. Despres JP, Lemieux I, SalomonH, et al. Effects ofmicronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial. J InternMed 2002; 251 (6): 490-9
18. Austin MA. Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype. Curr Atheroscler Rep 2000; 2 (3): 200-7
19. Davidson MH. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. AmJ Cardiol 2005; 96 (9A): 3K-13K
20. Idzior-Walus B, Sieradzki J, Rostworowski W, et al. Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest 2000; 30 (10): 871-8
21. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-61
22. Chew GT, Watts GF, Davis TM, et al. Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction. Diabetes Care 2008 Aug; 31 (8): 1502-9
23. Keating GM, Croom KF. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 2007; 67 (1): 121-53
24. Drazen JM, D'Agostino RB, Ware JH, et al. Ezetimibe and cancer - an uncertain association. N Engl J Med 2008 Sep 2; 359: 1398-9
25. Rossebø AB, Terje R, Pedersen TR, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008 Sep 2; 359: 1343-56